Figure 4. Imaging flow cytometry of CD9+/GFAP+/SVN+ exosomes in patients whose tumors progressed early (8.0-25.1 weeks) following initial vaccination.
CD9+/GFAP+/SVN+ exosomes at baseline (i.e. prior to first dose of vaccine) are shown in the left column, CD9+/GFAP+/SVN+ exosomes obtained from serum 8-24 weeks after first dose of vaccine (middle column) at the time of tumor progression, and in one patient (#7) at 25 weeks (right panel).